The use of monoclonal antibodies to fibroblast growth factor 23 (FGF23) was described as a therapy for hypophosphatemic rickets in a patient with a postzygotic c.182A > G mutation in the HRAS gene (20). Here, HRAS is linked to hypophosphatemic rickets.